Hunan Jingfeng Pharmaceutical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE000000Y11
CNY
8.14
-0.53 (-6.11%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
Net Sales
405.91
646.08
828.33
783.83
861.55
1,324.59
2,546.39
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
405.91
646.08
828.33
783.83
861.55
1,324.59
2,546.39
Raw Material Cost
172.89
228.98
234.09
353.61
375.94
579.41
665.62
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
40.41
42.00
52.57
86.54
108.13
105.64
85.17
Selling and Distribution Expenses
225.45
473.47
574.95
682.24
960.44
1,161.22
1,420.44
Other Expenses
-2.82
-0.64
-2.15
-5.25
11.66
7.60
6.55
Total Expenditure (Excl Depreciation)
410.55
738.07
840.14
1,069.85
1,561.07
1,922.27
2,236.77
Operating Profit (PBDIT) excl Other Income
-4.6000000000000005
-92
-11.799999999999999
-286
-699.5
-597.7
309.6
Other Income
-13.84
16.67
25.53
317.53
256.50
108.46
37.16
Operating Profit (PBDIT)
-2.70
-40.26
68.33
64.22
-364.70
-397.97
442.29
Interest
40.41
42.00
52.57
86.54
108.13
105.64
85.17
Exceptional Items
238.76
-64.04
-36.92
-6.11
-560.13
-305.16
-1.69
Gross Profit (PBDT)
233.02
417.10
594.24
430.22
485.61
745.18
1,880.77
Depreciation
29.19
47.00
60.39
123.67
113.33
98.76
104.75
Profit Before Tax
166.47
-193.31
-81.55
-152.10
-1,146.30
-907.53
250.68
Tax
5.08
32.84
9.62
46.20
3.39
1.78
45.23
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
152.30
-236.10
-122.56
-163.66
-1,068.51
-882.81
186.81
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
152.30
-236.10
-122.56
-163.66
-1,068.51
-882.81
186.81
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
7.14
8.64
27.31
-37.98
-86.79
-38.75
11.72
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
159.45
-227.46
-95.25
-201.64
-1,155.31
-921.55
198.54
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Reserves
81.80
-70.45
164.79
306.39
520.03
1,588.01
2,483.67
Earnings per share (EPS)
0.17
-0.27
-0.14
-0.19
-1.21
-1.0
0.21
Diluted Earnings per share
0.17
-0.27
-0.14
-0.19
-1.21
-1.0
0.21
Operating Profit Margin (Excl OI)
-4.45%
-16.09%
-2.12%
-48.09%
-85.26%
-45.69%
11.8%
Gross Profit Margin
48.2%
-22.64%
-2.55%
-3.63%
-119.9%
-61.06%
13.96%
PAT Margin
37.52%
-36.54%
-14.8%
-20.88%
-124.02%
-66.65%
7.34%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2024 is -37.18% vs -22.00% in Dec 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 170.07% vs -138.72% in Dec 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is 119.51% vs -232.94% in Dec 2023

stock-summary

Interest

YoY Growth in year ended Dec 2024 is -3.81% vs -20.15% in Dec 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has improved from Dec 2023

Compare Annual Results Of Hunan Jingfeng Pharmaceutical Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
405.91
0
405.91
Other Operating Income
0.00
0.00
0.00
Total Operating income
405.91
0
405.91
Raw Material Cost
172.89
0
172.89
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
40.41
0
40.41
Selling and Distribution Expenses
225.45
0
225.45
Other Expenses
-2.82
0.00
-2.82
Total Expenditure (Excl Depreciation)
410.55
0
410.55
Operating Profit (PBDIT) excl Other Income
-4.64
0.00
-4.64
Other Income
-13.84
0
-13.84
Operating Profit (PBDIT)
-2.70
0
-2.70
Interest
40.41
0
40.41
Exceptional Items
238.76
0
238.76
Gross Profit (PBDT)
233.02
0
233.02
Depreciation
29.19
0
29.19
Profit Before Tax
166.47
0
166.47
Tax
5.08
0
5.08
Provisions and contingencies
0
0
0.00
Profit After Tax
152.30
0
152.30
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
152.30
0
152.30
Share in Profit of Associates
0
0
0.00
Minority Interest
7.14
0
7.14
Other related items
0.00
0.00
0.00
Consolidated Net Profit
159.45
0
159.45
Equity Capital
0
0
0.00
Face Value
0.00
0
0.00
Reserves
81.80
0
81.80
Earnings per share (EPS)
0.17
0
0.17
Diluted Earnings per share
0.17
0
0.17
Operating Profit Margin (Excl OI)
-4.45%
0%
0.00
-4.45%
Gross Profit Margin
48.20%
0%
0.00
48.20%
PAT Margin
37.52%
0%
0.00
37.52%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 40.59 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is -37.18% vs -22.00% in Dec 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 15.94 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 170.07% vs -138.72% in Dec 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 1.11 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 119.51% vs -232.94% in Dec 2023

Annual - Interest
Interest 4.04 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is -3.81% vs -20.15% in Dec 2023

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) -4.45%
in Dec 2024

Figures in %
stock-summary

YoY Growth in year ended Dec 2024 has improved from Dec 2023